Tideglusib: Phase IIb data

The double-blind, European Phase IIb ARGO trial in 306 patients with mild to moderate AD showed that tideglusib missed the primary endpoint of improving ADAS-Cog score from baseline to week 26 vs. placebo. Noscira also said that tideglusib missed 2 secondary endpoints, but did not disclose details. Tideglusib was relatively well tolerated with no new safety concerns detected. Patients received placebo, once-daily 500 or 1,000 mg oral tideglusib, or 1,000 mg tideglusib given every other day for 26 weeks. Noscira said it plans to complete analyses of data from other secondary endpoints, subpopulations and biomarker and MRI assessments "in the following weeks." The company could not be reached for details. ...